MetaCap

Compugen (CGEN) vs Inhibikase Therapeutics (IKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Compugen (CGEN) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 20.3% versus a loss of 11.4%. Over five years, CGEN leads with a -59.5% price change compared with -89.3% for IKT. Inhibikase Therapeutics is the larger company by market cap ($185.2 million vs $174.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEN+20.26%IKT-11.41%
+108%+45%-19%
Nov 21, 20251 yearNov 20, 2026
CGEN-60.93%IKT-88.42%
+13%-42%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEN versus IKT key metrics
MetricCGENIKT
Share price$1.84$1.32
Market cap$174.29M$185.16M
1-day change-2.13%+1.54%
YTD return+20.26%-35.61%
1-year return+20.26%-11.41%
5-year return-59.47%-89.32%
P/E ratio (TTM)4.72—
EPS (TTM)$0.39$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.76M—
Revenue growth (YoY)+161.14%—
Net income (latest FY)$35.34M$-48.26M
Gross margin87.29%—
Operating margin43.05%—
Net margin48.57%—
52-week high$3.24$2.61
52-week low$1.43$1.28
Distance from 52-week high-43.21%-49.43%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+160.87%+320.45%
Average volume223.56K584.27K
Shares outstanding94.72M140.27M
Employees7535
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGEN has outperformed IKT by 31.7 percentage points over the past year.

About Compugen

CGEN stock →

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees

About Inhibikase Therapeutics

IKT stock →

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

CGEN vs IKT FAQ

Which is bigger, Compugen or Inhibikase Therapeutics?

Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $185.16M compared with $174.29M for Compugen (CGEN).

Which stock has performed better over the past year, CGEN or IKT?

CGEN returned +20.26% over the past 12 months, compared with -11.41% for IKT (price return, excluding dividends). Past performance does not predict future results.

Are Compugen and Inhibikase Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons